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• The fibrinolytic system participates in a variety of 
physiological and pathological processes. It consists of an 
inactive proenzyme, plasminogen, which can be activated to 
the active serine protease plasmin by the action of different 
types of plasminogen activators. The main function of the 
fibrinolytic system is to dissolve fibrin deposits in blood 
vessels. Thrombogenesis can be influenced by an insufficient 
or ineffective fibrinolytic system. The tissue-type plasminogen 
activator (t-PA) receives considerable attention since its 
deficiency has been shown to be a leading cause for 
thrombophilic situations. Increases of its main inhibitor 
(PAI) probably play a similar role. Using the advantages of 
recombinant DNA technology modem thrombolytic drugs 
based on the structure of plasminogen activators are applied 
for the therapy of thromboembolic diseases. Structure and 
function of the fibrinolytic system are outlined in the follow- 
ing review. Diagnostic evaluation of the fibrinolytic system 
and therapeutic considerations are discussed. 
INTRODUCTION 
• The principal role of the hemostatic mechanism is 
to protect the integrity of the vascular system. Blood 
coagulation and fibrinolysis are well-coordinated systems 
and the hemostatic balance depends upon a variety of 
interrelations including cellular (thrombocytes, endothe- 
lial cells, leukocytes) and humoral (activators, inhibitors) 
components (1). 
The purpose of this review is to consider how the 
fibrinolytic system participates in these processes under 
physiological and pathological conditions. It covers the 
nature of plasminogen activators (PA) and plasminogen 
activator inhibitors (PAI) and their involvement in various 
pathological situations. While the picture is far from being 
complete, diagnostic and therapeutic opportunities of 
plasminogen activators are discussed. 
THE FIBRINOLYTIC SYSTEM 
• The central reaction of the fibrinolytic system is the 
conversion of plasminogen, an inactive zymogen, to the 
active serine protease plasmin, which in turn degrades 
proteolytically a variety of substrates, including fibrin, 
fibrinogen and clotting factors Va and Villa (2). 
Two main pathways of plasminogen activation can 
be distinquished. Analogous to blood coagulation they are 
referred to as intrinsic and extrinsic pathways. 
Intrinsic activation (contact system-dependent path- 
way): The intrinsic activation of the fibrinolytic system is 
schematically shown in Figure 1. 
Factor XII (Hageman factor) is converted to its 
activated form (Xlla) when exposed to negatively charged 
surfaces. Factor Xlla activates prekallikrein to kallikrein. 
Kallikrein converts, possibly using the activation of an- 
other yet unidentified pro-activator, plasminogen to plas- 
min (3). The importance of this activation pathway is not 
yet clarified, however, it should be noted, that patients with 
Hageman factor deficiency may be at risk for thrombosis. 
EXTRINSIC ACTIVATION 
• This pathway has been receiving considerable at- 
tention. It consists of two activators and different types of 
inhibitors. The main components of the extrisic activation 
pathway are shown in Figure 2. 
The most important activator of plasminogen is the 
tissue type plasminogen activator (t-PA), which has been 
extensively characterized (4) and is recently being pro- 
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Figure 1: Intrinsic activation of the fibrinolytic system Figure 2: Extrinsic activation of the fibrinolytic system 
  
duced by recombinant DNA technology (5). Vascular 
endothelial cells are the main source of plasma t-PA, 
although it has been shown in thrombocytes, too. T-PA is 
secreted in its single chain form from the circulation. This 
release can be induced by various substances (thrombin, 
adrenaline, histamine), exercise and venous occlusion. 
Once in circulation, single-chain t-PA is quickly converted 
into its two-chain, disulfide-linked form by minimal 
amounts of free plasmin. Both forms of t-PA possess 
enzymatic activity, that is greatly enhanced in the presence 
of fibrin. The assembly of t-PA and plasminogen onto a 
fibrin surface accelerates the fibrinolysis and secures a 
relative clot specificity. 
Urine-type plasminogen activator (urokinase, u- 
PA) has been originally isolated from urine (6). It is 
produced by many different cell types (7). Single-chain 
and two-chain forms of urokinase are known. Single-chain 
urokinase is, contrary to single-chain t-PA, an inactive 
molecule. After conversion to the two-chain form it ex- 
presses fibrinolytic activity. Urokinase probably plays a 
minor role in the intravascular fibrinolysis and is rather 
important for pericellular proteolysis (cell migration, tis- 
sue destruction, tumor growth, tumor metastasis). Its 
usefulness as tumor marker has been reported (8). 
REGULATIOM OF THE FIBRIHOLYTIC SYSTEM 
• The fibrinolytic system is regulated by a fine net- 
work of plasminogen activators, plasminogen activator 
inhibitors and plasmin inhibitors. The two most important 
inhibitors are plasminogen activator inhibitor 1 (PAI-1) 
and alpha-2-antiplasmin. They belong to the serpin pro- 
tein family (SERine Protease INhibitors). 
At least four different plasminogen activator inhibi- 
tors have been described: 
PAI-1 endothelial cells, thrombocytes 
PAI-2 placenta, monocytes 
PAI-3 = protein C-inhibitor 
Nexin fibroblasts 
PAI-1 has been discovered in 1983 (9,10). PAI-1 is 
synthesized and secreted mainly from endothelial cells. It 
has been found also in thrombocytes, monocytes, smooth 
muscle cells and hepatocytes. It is biochemically well 
characterized (11). PAI-1 inactivates rapidly t-PA and u- 
PA in the circulation. The functionally active form of PAI- 
1 in plasma is bound to the plasma protein vitronectin, 
possibly to stabilize the active conformation and to protect 
the molecule against oxidation, which causes irreversible 
inactivation. 
A second type of plasminogen activator inhibitor, 
PAI-2, has been recently isolated from placenta. It seems 
to be mainly an urokinase inhibitor (12). Its role in 
physiology and pathology is not yet understood. 
PAI-3 is identical to the protein C inhibitor. It is 
rather a weak inhibitor of plasminogen activators. In 
addition, the potein C - thrombomodulin system promotes 
fibrinolysis by inactivating PAI-1 through activated pro- 
tein C (13). The importance of this slow reaction is not yet 
clarified. 
The fibroblast-derived protease nexin possesses 
PAI activity. It is absent from plasma and therfore rather 
linked to extravascular fibrinolysis. 
Alpha-2-antiplasmin is the main plasmin inhibitor 
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formation of 1:1 complexes. It is secreted by the liver and 
circulates at concentration of 70 mg/1. 
ROLE OF THE FIBRIfJOLYTIC SYSTEM IN 
THROMBOGEHESIS 
• The most important role of the fibrinolytic system is 
the degradation of fibrin deposits in blood vessels. There- 
fore it seems to be reasonable to link a defective or 
insufficient fibrinolytic system with the pathophysiology of 
thrombosis and thrombogenesis itself. 
Using histochemical methods Isacson and Nilsson 
demonstrated in 1972 that patients suffering from deep 
venous thrombosis had decreased content of plasminogen 
activators in their vessel walls (14). Korninger et al fol- 
lowed a group of 121 patients with recurrent venous 
thrombosis for some years and found a correlation be- 
tween the recurrence rate and a defective fibrinolytic 
system (15). 
Methods for the measurements of specific param- 
eters of the fibrinolytic system (activators, inhibitors) 
became available with the increasing knowledge of both 
structure and function of the various components of the 
fibrinolytic sustem. Subsequently, studies of the fibrino- 
lytic system in patients suffering from venous thrombosis 
were performed (16-19). All these studies revealed that 30 
- 40 % of the patients were found to have impaired 
fibrinolytic activity. The underlying mechanism were dif- 
ferent - in some cases low basal t-PA levels or insufficient 
release were found, other patients showed an increased 
inhibitor activity. Combination of booth defects were 
described too. All these studies are retrospective. Pro- 
spective studies are needed for the evaluation of the 
predictive value of the fibrinolytic parameters. 
In the past few years there is growing evidence 
supporting a role of the fibrinolytic system in arterial 
thrombosis including coronary thrombosis. Hamsten et al. 
reported in 1985 on increased PAI activities in myocardial 
infarction patients (20). The connection between increased 
PAI activities and development of myocardial. infarction 
has been confirmed (21). 
Impairment of the fibrinolytic system due to de- 
creased t-PA or increased PAI represent the vast majority 
of all cases of hypofibrinolysis. Other possible and de- 
scribed abnormalities leading to decreased fibrinolytic 
activity are deficiencies or molecular defects of plasmino- 
gen (22), increased alpha-2-antiplasmin activity and 
dysfibrinogenemia. Impaired fibrinolytic activity is associ- 
ated with some of the well-established risk factors for the 
development of coronary heart disease such as smoking, 
hyperlipoproteinemia, diabetes and obesity. 
The fibrinolytic system seems to be under the 
influence of physical exercise and nutritional status. Physi- 
cal exercise and food rich in fruits and vegetables reduce 
PAI activity (23,24). 
DIAGNOSTIC EVALUATION OF THE FIBRIHOLYTIC SYSTEM 
• It is now generally accepted that patients with 
defective or insufficient fibrinolytic system are at risk for 
venous thrombosis (25, 26). In addition there is growing 
evidence supporting the pathogenetic role of decreased 
fibrinolytic activity in coronary heart disease and acute 
myocardial infarction (21). Clinical manifestation may 
vary, but thrombosis in patients younger than 45 years 
without any underlying disease or risk factor, reccurent 
thrombotic events and multiple thromboembolic manifes- 
tations within a family, should engage the clinician to- 
perform a complex laboratory program in order to inves- 
tigate possible causes of inherited or acquired thrombo- 
philia. 
Several diagnostic programs have been proposed 
(27, 28). Diagnostic programs should include investiga- 
tion of increased coagulation sysem activity, increased 
platelet activity, coagulation inhibitor deficiency and de- 
creased fibrinolytic system activity (29). 
Two general types of tests may be used for the 
evaluation of the fibrinolytic system 
a) screening tests 
b) measurements of specific parameters 
Screening tests are employed in order to obtain 
information about the overall activity of the fibrinolytic 
system. Usually euglobulin fractions of human plasma 
prior to and after an appropiate stimulation (e. g. venous 
occlusion, vasopressin analogue) are used. The euglobulin 
fraction contains fibrinogen, plasminogen, t-PA and a 
portion of PAI-1. It lacks, however, u-PA, alpha-2- 
antiplasmin and a fraction of PAI-1. 
Using the euglobulin clot lysis time, a significant 
shortening of the time, necessary to dissolve the clot is 
measured after venous occlusion (from approximately 4 
hours to 20 - 60 minutes). This shortening is less pro- 
nounced or absent in patients with insufficient fibrinolytic 
activity. The eugloblin clot lysis time correlates with 
increased values of PAI-1. 
The fibrin plate method is another widely used 
screening test (30). Little amounts of euglobulin fractions 
are applied onto a plasminogen-rich fibrin preparation in 
flat dishes and the areas of fibrin lysis are measured prior 
to and after venous occlusion. The increase of lysis area 
correlates with the t-PA activity of the sample. This test 
does not depend on the patient's own fibrinogen and 
plasminogen. 
Another approprate screening test is the fibrin 
difference assay. The test depends upon the ability of 
human plasma to dissolve a defined fibrin clot. Normally 
the test results are between 80 and 100. Values below 30% 
may indicate a lowered fibrinolytic activity (31, 32). 
The three described screening tests allow to differ- 
entiate between responders showing impaired basal fi- 
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brinolytic activity and/or insufficient increase after venous 
occlusion (33). 
Every identification of a hypof ibrinolytic state should 
be followed by measurements of specific components of 
the fibrinolytic system. 
The principal proenzyme of the fibrinolytic system, 
plasminogen, is determined by activity meausurements 
using chromogenic substrates (S-2251). Decreased activi- 
ty should be clarified (dysproteinemia, hypoplasm- 
inogenemia). A few hypofibrinolytic situations due to 
deficiency or abnormalities of plasminogen have been 
described (22). 
Tissue-type plasminogen activator can be charac- 
terized by activity and antigen measurements. Determina- 
tion of t-PA activity should be preffered since the estima- 
tion of t-PA antigen should not necessarily reflect its 
activity. Measurements of t-PA are usually performed 
prior to and after venous occlusion. Increase of at least 
50% is accepted as marker for appropriate stimulation. 
Decreased basal activities and/or inappropiate increase of 
t-PA after stimulation are frequently found in patients with 
venous thrombosis (34). 
Measurement of plasminogen activator inhibitor 
activity should be performed, since an increased PAI 
activity could contribute to hypofibrinolysis. Basal PAI 
activities vary widely. It is recommended that PAI activity 
should be measured prior to and after venous occlusion 
(35). High PAI activities after occlusion are thought to 
overcome the release of t-PA from the endothelial cell, 
making the fibrinolytic response ineffective. High basal 
PAI activities have been found frequently in patients 
suffering from recurrent deep venous thrombosis (32). 
The measurement of other components of the fi- 
brinolytic system is either difficult to perform (u-PA) or of 
suspect clinical significance (alpha-2antiplasmin). 
We recommend for the evaluation of the fibrino- 
lytic system first to apply a screening test, and in case of 
pathological results, the determination of PAI and t-PA 
prior to and after venous occlusion. 
Since the fibrinolytic system is very dynamic, all 
tests should be applied repeatedly in order to avoid mis- 
leading conclusions concerning its activity. 
THERAPEUTIC APPLICATION OF PLASM1MOGEH 
ACTIVATORS 
•       Thromboembolic diseases of the cardiovascular 
system are a main cause of death and disability. 
Consequently, therapeutic application of plasmino- 
gen activators has been introduced with the increasing 
knowledge of physiology and pathology of the fibrinolytic 
system (36). Three generations of fibrinolytic (thrombolytic) 
drugs based on plasminogen activators can be distinquished: 
a) first generation: streptokinase, urokinase 
b) second generation: t-PA, single-chain u-PA, 
acylated plasminogen streptokinase activator complex 
c) third generation: gene technology-derived plas- 
minogen activators, hybrid molecules, mutants, antibody- 
targeted activators 
Thrombolytic therapy using streptokinase or uroki- 
nase is established as a well-known and realistic form of 
treatment for venous thrombosis, pulmonary embolism 
and acute myocardial infarction; however, optimal dose 
regimen and exact place in the therapy of thromboembolic 
deseases are still controversial. Disadvantages include 
difficult dosage and bleeding risk, resulting from non- 
fibrin specificity. 
Initial therapeutic studies with t-PA and single- 
chain t-PA were performed with their availability in small 
amounts. Higher fibrin-specific thrombolytic efficacy and 
absence of systemic fibrinolytic activation were confirmed. 
The advantages of recombinant DNA technology 
contribute to the applicability of plasminogen activators 
for therapy. Recombinant t-PA (rt-PA) seems to be the 
drug of choice for treatment of acute myocardial infarction, 
resulting in successful reperfusion in about 65 % of inf arct- 
related arteries. Reocclusion rates vary between 10 and 
15% in large trials. Therapeutic application of recombi- 
nant single chain u-PA in acute myocardial infarction has 
given similar results. 
New trends in thrombolytic therapy include im- 
provement of fibrin specifity of recombinant plasminogen 
activators and construction of mutants with prolonged in 
vivo half-life. Several hybrid (chimeric) plasminogen acti- 
vator molecules have been produced. 
Plasminogen activators have been coupled to fibrin- 
specific antibodies to improve clot-specific lysis (37). 
These alternatives are currently being investigated. Fur- 
ther developments in this field may be expected from 
ongoing basic and clinical research. 
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